Ceribell, Inc. (CBLL): R&D Expense
$19.14M
Year ended 2025-12-31
$22.95M
Trailing 12 months to 2026-06-30
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $19.14M | +41.2% | 2026-02-24, From 2025-01-01 |
| 2024-12-31 | $13.56M | +50.8% | 2026-02-24, From 2024-01-01 |
| 2023-12-31 | $8.99M | n/a | 2025-02-25, From 2023-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Ceribell, Inc. (CBLL) | 2025-12-31 | $19.14M | +41.2% |
| Vaso Corp (VASO) | 2025-12-31 | $728.0K | -14.5% |
| Biolife Solutions Inc (BLFS) | 2025-12-31 | $7.57M | +59.3% |
| Electromed, Inc. (ELMD) | 2026-06-30 | $1.31M | +31.9% |
| Outset Medical, Inc. (OM) | 2025-12-31 | $21.23M | -44.7% |
| Iridex Corp (IRIX) | 2026-01-03 | $3.67M | -32.7% |
| Axogen, Inc. (AXGN) | 2025-12-31 | $32.88M | +18.4% |
| Stereotaxis, Inc. (STXS) | 2025-12-31 | $9.38M | -3.9% |
| electroCore, Inc. (ECOR) | 2024-12-31 | $2.36M | -55.6% |
Compare CBLL, VASO, BLFS, ELMD side by side · Screen every company in Electromedical & Electrotherapeutic Apparatus ↗